Target: Francis S. Collins, Director of the National Institute for Health
Goal: Conduct clinical trials that are more representative of minority groups
About half of the nation’s population is being affected by a major barrier that is limiting adequate research in clinical trials that test the efficacy and safety of medications and medical devices by observing their effects on large groups of people. A recent study from the University of California has shown that on average, minorities account for 5% of participants in clinical trials and only 2% of cancer trials. Since certain diseases and cancers disproportionately affect minority groups, there must be more effort put into facilitating trials that are more representative of the population the illnesses affect the most.
If a disease is affecting a particular group at a higher rate, that group should be studied closely in order to conduct more significant research. A recent study shows that African American women are 40% more likely to die from breast cancer than Caucasian women. Another study shows that Mexican-Americans and Puerto Rican Americans are more prone to type two diabetes. Characteristics between groups are an important factor that can affect results from these trials and by neglecting to be inclusive, it can decelerate the development of effective treatments and therapies.
Clinical trials are essential to the development of therapies and participant diversity is vital to yield meaningful results that are representative of the population. Demand that more effort is put into achieving this. By signing this petition, you will help urge the Directory of the National Institute of Health to implement policies that require clinical trials to be more representative of minority groups.
Dear Francis S. Collins,
I am very concerned about the vast under-representation of minority groups in clinical trials. There are certain diseases and cancers that affect minority groups at a much higher rate, but these groups only account for 5% of participants in clinical trials. More effort must be made in order to make clinical trials more representative of the population these diseases affect the most. Trials that do not have a diverse participant group are not as helpful because characteristics between groups can limit results and decelerate the development of treatments.
This is a major issue that needs immediate attention because it affects about half of our nation’s population. Please ensure that minority groups are better represented in clinical trials in order to conduct more meaningful research that can lead to effective treatments and therapies.
[Your Name Here]
Photo Credit: Fae via Wikipedia